10725819
Cancer, hrr
https://raw.githubusercontent.com/jamesd4335/hrr2/master/hrr_pipes.csl
50
date
desc
187
https://healthresearchreport.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22ZCYFNG5H%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Qin%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EPharmacological%20vitamin%20C%20inhibits%20mTOR%20signaling%20and%20tumor%20growth%20by%20degrading%20Rictor%20and%20inducing%20HMOX1%20expression%3C%5C%2Fb%3E%23%23%212023%20%7C%20Qin%20S%2C%20Wang%20G%2C%20et%20al.%20%7C%20%3Ci%3EPLOS%20Genetics%3C%5C%2Fi%3E.%202023%3B19%282%29%3Ae1010629.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgen.1010629%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgen.1010629%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacological%20vitamin%20C%20inhibits%20mTOR%20signaling%20and%20tumor%20growth%20by%20degrading%20Rictor%20and%20inducing%20HMOX1%20expression%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Senlin%22%2C%22lastName%22%3A%22Qin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guoyan%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lei%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huijun%22%2C%22lastName%22%3A%22Geng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yining%22%2C%22lastName%22%3A%22Zheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Xia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shengru%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junhu%22%2C%22lastName%22%3A%22Yao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lu%22%2C%22lastName%22%3A%22Deng%22%7D%5D%2C%22abstractNote%22%3A%22Pharmacological%20vitamin%20C%20%28VC%29%20is%20a%20potential%20natural%20compound%20for%20cancer%20treatment.%20However%2C%20the%20mechanism%20underlying%20its%20antitumor%20effects%20remains%20unclear.%20In%20this%20study%2C%20we%20found%20that%20pharmacological%20VC%20significantly%20inhibits%20the%20mTOR%20%28including%20mTORC1%20and%20mTORC2%29%20pathway%20activation%20and%20promotes%20GSK3-FBXW7-mediated%20Rictor%20ubiquitination%20and%20degradation%20by%20increasing%20the%20cellular%20ROS.%20Moreover%2C%20we%20identified%20that%20HMOX1%20is%20a%20checkpoint%20for%20pharmacological-VC-mediated%20mTOR%20inactivation%2C%20and%20the%20deletion%20of%20FBXW7%20or%20HMOX1%20suppresses%20the%20regulation%20of%20pharmacological%20VC%20on%20mTOR%20activation%2C%20cell%20size%2C%20cell%20viability%2C%20and%20autophagy.%20More%20importantly%2C%20it%20was%20observed%20that%20the%20inhibition%20of%20mTOR%20by%20pharmacological%20VC%20supplementation%20in%20vivo%20produces%20positive%20therapeutic%20responses%20in%20tumor%20growth%2C%20while%20HMOX1%20deficiency%20rescues%20the%20inhibitory%20effect%20of%20pharmacological%20VC%20on%20tumor%20growth.%20These%20results%20demonstrate%20that%20VC%20influences%20cellular%20activities%20and%20tumor%20growth%20by%20inhibiting%20the%20mTOR%20pathway%20through%20Rictor%20and%20HMOX1%2C%20which%20may%20have%20therapeutic%20potential%20for%20cancer%20treatment.%22%2C%22date%22%3A%22Feb%2014%2C%202023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pgen.1010629%22%2C%22ISSN%22%3A%221553-7404%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosgenetics%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pgen.1010629%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-02-15T19%3A12%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22VYFVN7TK%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhe%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EAscorbate%20oxidase-like%20nanozyme%20with%20high%20specificity%20for%20inhibition%20of%20cancer%20cell%20proliferation%20and%20online%20electrochemical%20DOPAC%20monitoring%3C%5C%2Fb%3E%23%23%212023%20%7C%20Zhe%20Y%2C%20Wang%20J%2C%20et%20al.%20%7C%20%3Ci%3EBiosensors%20and%20Bioelectronics%3C%5C%2Fi%3E.%202023%3B220%3A114893.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bios.2022.114893%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bios.2022.114893%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ascorbate%20oxidase-like%20nanozyme%20with%20high%20specificity%20for%20inhibition%20of%20cancer%20cell%20proliferation%20and%20online%20electrochemical%20DOPAC%20monitoring%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yadong%22%2C%22lastName%22%3A%22Zhe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jialu%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhiqiang%22%2C%22lastName%22%3A%22Zhao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guoyuan%22%2C%22lastName%22%3A%22Ren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jingjie%22%2C%22lastName%22%3A%22Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kai%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuqing%22%2C%22lastName%22%3A%22Lin%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20extensive%20investigation%20of%20the%20nanozymes%20exhibit%20their%20favorable%20performance%20compared%20to%20natural%20enzymes%2C%20nevertheless%2C%20the%20highly%20specific%20nanozyme%20still%20needs%20to%20be%20developed%20so%20that%20it%20can%20meet%20the%20requirements%20of%20exploring%20the%20mechanism%20as%20well%20as%20administration%20of%20related%20diseases%20and%20selective%20monitoring%20in%20biological%20system.%20In%20this%20study%2C%20self-assembled%20glutathione-Cu%5C%2FCu2O%20nanoparticles%20%28GSH-Cu%5C%2FCu2O%20NPs%29%20that%20exhibits%20specific%20ascorbic%20acid%20%28AA%29%20oxidase-like%20catalytic%20activity%20were%20constructed%20for%20AA-activated%20and%20H2O2-reinforced%20cancer%20cell%20proliferation%20inhibition%20and%20selective%20neurochemical%20monitoring.%20Cu%5C%2FCu2O%20NPs%20demonstrates%20effective%20AA%20oxidase-like%20activity%20and%20no%20common%20characteristics%20of%20other%20redox%20mimic%20enzymes%20often%20present%20in%20nanozyme.%20In%20particular%2C%20we%20found%20that%20the%20AA%20oxidase-like%20activity%20of%20GSH-Cu%5C%2FCu2O%20nanozyme%20was%20significantly%20improved%20by%20about%2040%25%20by%20improving%20the%20activation%20ability%20toward%20oxygen.%20The%20synthesized%20nanozyme%20can%20induce%20the%20generation%20of%20active%20oxygen%20by%20accelerating%20the%20oxidation%20of%20AA%2C%20which%20effectively%20suppresses%20the%20proliferation%20of%20cancer%20cells.%20We%20constructed%20an%20online%20electrochemical%20system%20%28OECS%29%20though%20loading%20nanozyme%20with%20enhanced%20ascorbate%20oxidase%20activity%20into%20a%20microreactor%20and%20setting%20it%20in%20the%20upstream%20of%20the%20detector.%20This%20GSH-Cu%5C%2FCu2O%20NPs-integrated%20microreactor%20can%20completely%20eliminate%20AA%20interference%20of%20the%20physical%20level%20toward%203%2C4-dihydroxy%20phenylacetic%20acid%20%28DOPAC%29%20electrochemical%20measurement%2C%20and%20the%20nanozyme-based%20OECS%20is%20able%20to%20continuously%20capture%20DOPAC%20alteration%20in%20rat%20brain%20acidosis%20model.%20Our%20findings%20may%20inspire%20rational%20design%20of%20nanozymes%20with%20high%20specificity%20as%20well%20as%20nanozyme-based%20selectivity%20solution%20for%20in%20vivo%20detection%20and%20show%20promising%20opportunities%20for%20their%20involvement%20in%20neurochemistry%20investigation.%22%2C%22date%22%3A%222023-01-15%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bios.2022.114893%22%2C%22ISSN%22%3A%220956-5663%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0956566322009332%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22WXLQ5C6Q%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Begimbetova%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EThe%20Oxidative%20Drug%20Combination%20for%20Suppressing%20KRAS%20G12D%20Inducible%20Tumour%20Growth%3C%5C%2Fb%3E%23%23%212022%20%7C%20Begimbetova%20D%2C%20Kukanova%20A%2C%20et%20al.%20%7C%20%3Ci%3EBiomed%20Res%20Int%3C%5C%2Fi%3E.%202022%3B2022%3A9426623.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1155%5C%2F2022%5C%2F9426623%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1155%5C%2F2022%5C%2F9426623%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Oxidative%20Drug%20Combination%20for%20Suppressing%20KRAS%20G12D%20Inducible%20Tumour%20Growth%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dinara%22%2C%22lastName%22%3A%22Begimbetova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Assiya%22%2C%22lastName%22%3A%22Kukanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Fazyl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenzhekyz%22%2C%22lastName%22%3A%22Manekenova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Talgat%22%2C%22lastName%22%3A%22Omarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agata%20N.%22%2C%22lastName%22%3A%22Burska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Medina%22%2C%22lastName%22%3A%22Khamijan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandr%22%2C%22lastName%22%3A%22Gulyayev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bakytgul%22%2C%22lastName%22%3A%22Yermekbayeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abay%22%2C%22lastName%22%3A%22Makishev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timur%22%2C%22lastName%22%3A%22Saliev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanat%22%2C%22lastName%22%3A%22Batyrbekov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chokan%22%2C%22lastName%22%3A%22Aitbayev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhanat%22%2C%22lastName%22%3A%22Spatayev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dos%22%2C%22lastName%22%3A%22Sarbassov%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20Kirsten%20rat%20sarcoma%20%28KRAS%29%20protein%20is%20an%20essential%20contributor%20to%20the%20development%20of%20pancreatic%20ductal%20adenocarcinoma%20%28PDAC%29.%20KRAS%20G12D%20and%20G12V%20mutant%20tumours%20are%20significant%20challenges%20in%20cancer%20therapy%20due%20to%20high%20resistance%20to%20the%20treatment.%20%5Cn%5CnObjective%5Cn%20To%20determine%20how%20effective%20is%20the%20ATO%5C%2FD-VC%20combination%20in%20suppression%20of%20PDAC%20the%20mouse%20transgenic%20model.%20This%20study%20investigated%20the%20antitumour%20effect%20of%20a%20novel%20combination%20of%20arsenic%20trioxide%20%28ATO%29%20and%20D-ascorbic%20acid%20isomer%20%28D-VC%29.%20Such%20a%20combination%20can%20be%20used%20to%20treat%20KRAS%20mutant%20cancer%20by%20inducing%20catastrophic%20oxidative%20stress.%20%5Cn%5CnMethods%5Cn%20In%20this%20study%2C%20we%20examined%20the%20effectiveness%20of%20ATO%20and%20D-VC%20on%20xenograft%20models%5Cu2014AK192%20cells%20transplanted%20into%20mice.%20Previously%2C%20it%20has%20been%20shown%20that%20a%20high%20concentration%20of%20Vitamin%20C%20%28VC%29%20selectively%20can%20kill%20the%20cells%20expressing%20KRAS.%20%5Cn%5CnResults%5Cn%20The%20results%20of%20this%20study%20demonstrated%20that%20the%20combination%20of%20VC%20with%20a%20low%20dose%20of%20the%20oxidizing%20drug%20ATO%20led%20to%20the%20enhancement%20of%20the%20therapeutic%20effect.%20These%20findings%20suggest%20that%20the%20combined%20treatment%20using%20ATO%20and%20D-VC%20is%20a%20promising%20approach%20to%20overcome%20the%20limitation%20of%20drug%20selectivity%20and%20efficacy.%22%2C%22date%22%3A%222022-12-30%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1155%5C%2F2022%5C%2F9426623%22%2C%22ISSN%22%3A%222314-6133%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9822755%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-19T13%3A45%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22J2L636KW%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Burska%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EEnhancing%20an%20Oxidative%20%26%23x201C%3BTrojan%20Horse%26%23x201D%3B%20Action%20of%20Vitamin%20C%20with%20Arsenic%20Trioxide%20for%20Effective%20Suppression%20of%20KRAS-Mutant%20Cancers%3A%20A%20Promising%20Path%20at%20the%20Bedside%3C%5C%2Fb%3E%23%23%212022%20%7C%20Burska%20AN%2C%20Ilyassova%20B%2C%20et%20al.%20%7C%20%3Ci%3ECells%3C%5C%2Fi%3E.%202022%3B11%2821%29%3A3454.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcells11213454%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcells11213454%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Enhancing%20an%20Oxidative%20%5Cu201cTrojan%20Horse%5Cu201d%20Action%20of%20Vitamin%20C%20with%20Arsenic%20Trioxide%20for%20Effective%20Suppression%20of%20KRAS-Mutant%20Cancers%3A%20A%20Promising%20Path%20at%20the%20Bedside%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agata%20N.%22%2C%22lastName%22%3A%22Burska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bayansulu%22%2C%22lastName%22%3A%22Ilyassova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aruzhan%22%2C%22lastName%22%3A%22Dildabek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Medina%22%2C%22lastName%22%3A%22Khamijan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dinara%22%2C%22lastName%22%3A%22Begimbetova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferdinand%22%2C%22lastName%22%3A%22Moln%5Cu00e1r%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dos%20D.%22%2C%22lastName%22%3A%22Sarbassov%22%7D%5D%2C%22abstractNote%22%3A%22The%20turn-on%20mutations%20of%20the%20KRAS%20gene%2C%20coding%20a%20small%20GTPase%20coupling%20growth%20factor%20signaling%2C%20are%20contributing%20to%20nearly%2025%25%20of%20all%20human%20cancers%2C%20leading%20to%20highly%20malignant%20tumors%20with%20poor%20outcomes.%20Targeting%20of%20oncogenic%20KRAS%20remains%20a%20most%20challenging%20task%20in%20oncology.%20Recently%2C%20the%20specific%20G12C%20mutant%20KRAS%20inhibitors%20have%20been%20developed%20but%20with%20a%20limited%20clinical%20outcome%20because%20they%20acquire%20drug%20resistance.%20Alternatively%2C%20exploiting%20a%20metabolic%20breach%20of%20KRAS-mutant%20cancer%20cells%20related%20to%20a%20glucose-dependent%20sensitivity%20to%20oxidative%20stress%20is%20becoming%20a%20promising%20indirect%20cancer%20targeting%20approach.%20Here%2C%20we%20discuss%20the%20use%20of%20a%20vitamin%20C%20%28VC%29%20acting%20in%20high%20dose%20as%20an%20oxidative%20%5Cu201cTrojan%20horse%5Cu201d%20agent%20for%20KRAS-mutant%20cancer%20cells%20that%20can%20be%20potentiated%20with%20another%20oxidizing%20drug%20arsenic%20trioxide%20%28ATO%29%20to%20obtain%20a%20potent%20and%20selective%20cytotoxic%20impact.%20Moreover%2C%20we%20outline%20the%20advantages%20of%20VC%5Cu2019s%20non-natural%20enantiomer%2C%20D-VC%2C%20because%20of%20its%20distinctive%20pharmacokinetics%20and%20lower%20toxicity.%20Thus%2C%20the%20D-VC%20and%20ATO%20combination%20shows%20a%20promising%20path%20to%20treat%20KRAS-mutant%20cancers%20in%20clinical%20settings.%22%2C%22date%22%3A%222022-11-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcells11213454%22%2C%22ISSN%22%3A%222073-4409%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9657932%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22TL67GEIM%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Morante-Palacios%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EVitamin%20C%20enhances%20NF-%26%23x3BA%3BB-driven%20epigenomic%20reprogramming%20and%20boosts%20the%20immunogenic%20properties%20of%20dendritic%20cells%3C%5C%2Fb%3E%23%23%212022%20%7C%20Morante-Palacios%20O%2C%20Godoy-Tena%20G%2C%20et%20al.%20%7C%20%3Ci%3ENucleic%20Acids%20Res%3C%5C%2Fi%3E.%202022%3B50%2819%29%3A10981-10994.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnar%5C%2Fgkac941%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnar%5C%2Fgkac941%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Vitamin%20C%20enhances%20NF-%5Cu03baB-driven%20epigenomic%20reprogramming%20and%20boosts%20the%20immunogenic%20properties%20of%20dendritic%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Octavio%22%2C%22lastName%22%3A%22Morante-Palacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Godoy-Tena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josep%22%2C%22lastName%22%3A%22Calafell-Segura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Ciudad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20M%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-C%5Cu00e1ceres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22Sardina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esteban%22%2C%22lastName%22%3A%22Ballestar%22%7D%5D%2C%22abstractNote%22%3A%22Dendritic%20cells%20%28DCs%29%2C%20the%20most%20potent%20antigen-presenting%20cells%2C%20are%20necessary%20for%20effective%20activation%20of%20na%5Cu00efve%20T%20cells.%20DCs%5Cu2019%20immunological%20properties%20are%20modulated%20in%20response%20to%20various%20stimuli.%20Active%20DNA%20demethylation%20is%20crucial%20for%20DC%20differentiation%20and%20function.%20Vitamin%20C%2C%20a%20known%20cofactor%20of%20ten-eleven%20translocation%20%28TET%29%20enzymes%2C%20drives%20active%20demethylation.%20Vitamin%20C%20has%20recently%20emerged%20as%20a%20promising%20adjuvant%20for%20several%20types%20of%20cancer%3B%20however%2C%20its%20effects%20on%20human%20immune%20cells%20are%20poorly%20understood.%20In%20this%20study%2C%20we%20investigate%20the%20epigenomic%20and%20transcriptomic%20reprogramming%20orchestrated%20by%20vitamin%20C%20in%20monocyte-derived%20DC%20differentiation%20and%20maturation.%20Vitamin%20C%20triggers%20extensive%20demethylation%20at%20NF-%5Cu03baB%5C%2Fp65%20binding%20sites%2C%20together%20with%20concordant%20upregulation%20of%20antigen-presentation%20and%20immune%20response-related%20genes%20during%20DC%20maturation.%20p65%20interacts%20with%20TET2%20and%20mediates%20the%20aforementioned%20vitamin%20C-mediated%20changes%2C%20as%20demonstrated%20by%20pharmacological%20inhibition.%20Moreover%2C%20vitamin%20C%20increases%20TNF%5Cu03b2%20production%20in%20DCs%20through%20NF-%5Cu03baB%2C%20in%20concordance%20with%20the%20upregulation%20of%20its%20coding%20gene%20and%20the%20demethylation%20of%20adjacent%20CpGs.%20Finally%2C%20vitamin%20C%20enhances%20DC%5Cu2019s%20ability%20to%20stimulate%20the%20proliferation%20of%20autologous%20antigen-specific%20T%20cells.%20We%20propose%20that%20vitamin%20C%20could%20potentially%20improve%20monocyte-derived%20DC-based%20cell%20therapies.%22%2C%22date%22%3A%222022-10-28%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fnar%5C%2Fgkac941%22%2C%22ISSN%22%3A%220305-1048%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9638940%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-19T14%3A29%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22PI5VNHNW%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22van%20Gorkom%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3ENo%20Effect%20of%20Vitamin%20C%20Administration%20on%20Neutrophil%20Recovery%20in%20Autologous%20Stem%20Cell%20Transplantation%20for%20Myeloma%20or%20Lymphoma%3A%20A%20Blinded%2C%20Randomized%20Placebo-Controlled%20Trial%3C%5C%2Fb%3E%23%23%212022%20%7C%20van%20Gorkom%20GNY%2C%20Boerenkamp%20LS%2C%20et%20al.%20%7C%20%3Ci%3ENutrients%3C%5C%2Fi%3E.%202022%3B14%2822%29%3A4784.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fnu14224784%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fnu14224784%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22No%20Effect%20of%20Vitamin%20C%20Administration%20on%20Neutrophil%20Recovery%20in%20Autologous%20Stem%20Cell%20Transplantation%20for%20Myeloma%20or%20Lymphoma%3A%20A%20Blinded%2C%20Randomized%20Placebo-Controlled%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwendolyn%20N.%20Y.%22%2C%22lastName%22%3A%22van%20Gorkom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20S.%22%2C%22lastName%22%3A%22Boerenkamp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgit%20L.%20M.%20G.%22%2C%22lastName%22%3A%22Gijsbers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heidi%20H.%22%2C%22lastName%22%3A%22van%20Ojik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Will%20K.%20W.%20H.%22%2C%22lastName%22%3A%22Wodzig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lotte%22%2C%22lastName%22%3A%22Wieten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catharina%20H.%20M.%20J.%22%2C%22lastName%22%3A%22Van%20Elssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%20M.%20J.%22%2C%22lastName%22%3A%22Bos%22%7D%5D%2C%22abstractNote%22%3A%22Vitamin%20C%20is%20an%20important%20micronutrient%20for%20various%20immune%20cells.%20It%20increases%20phagocytic%20cell%20function%20and%20is%20necessary%20for%20T%20and%20natural%20killer%20%28NK%29%20cell%20development.%20Patients%20in%20need%20of%20an%20autologous%20hematopoietic%20stem%20cell%20transplantation%20%28HSCT%29%20are%20often%20vitamin%20C-depleted.%20We%20therefore%20hypothesized%20that%20vitamin%20C%20supplementation%20could%20improve%20immune%20recovery%20in%20autologous%20HSCT%20patients.%20This%20blinded%2C%20placebo-controlled%20trial%20included%2044%20patients%20randomized%20to%20receive%20vitamin%20C%20or%20a%20placebo.%20The%20following%20outcome%20measures%20used%20were%20clinical%20and%20immunological%20parameters%2C%20among%20others%3A%20time%20to%20neutrophil%20recovery%2C%20serum%2C%20and%20intracellular%20vitamin%20C%20values.%20Twenty-one%20patients%20received%20vitamin%20C%2C%20and%2023%20received%20a%20placebo.%20The%20time%20to%20neutrophil%20recovery%20did%20not%20differ%20between%20the%20two%20groups%20at%2011.2%20days%20%28p%20%3D%200.96%29.%20There%20were%20no%20differences%20in%20hospitalization%20time%20%2819.7%20vs.%2019.1%20days%2C%20p%20%3D%200.80%29%2C%20the%20incidence%20of%20neutropenic%20fever%20%2857%25%20vs.%2078%25%2C%20p%20%3D%200.20%29%2C%20or%203-month%20overall%20survival%20%2890.5%25%20vs.%20100%25%2C%20p%20%3D%200.13%29.%20Bacteremia%20seemed%20to%20occur%20less%20in%20the%20vitamin%20C%20group%20%2810%25%20vs.%2035%25%2C%20p%20%3D%200.07%29.%20Our%20study%20shows%20no%20benefit%20from%20vitamin%20C%20supplementation%20on%20neutrophil%20recovery%20and%20hospitalization%2C%20despite%20possible%20lower%20rates%20of%20bacteremia%20in%20the%20vitamin%20C%20group.%20Therefore%2C%20we%20do%20not%20advise%20vitamin%20C%20supplementation%20in%20this%20treatment%20group.%22%2C%22date%22%3A%222022%5C%2F1%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fnu14224784%22%2C%22ISSN%22%3A%222072-6643%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6643%5C%2F14%5C%2F22%5C%2F4784%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22DUPMLYE5%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zasowska-Nowak%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EHigh-Dose%20Vitamin%20C%20in%20Advanced-Stage%20Cancer%20Patients%3C%5C%2Fb%3E%23%23%212021%20%7C%20Zasowska-Nowak%20A%2C%20Nowak%20PJ%2C%20et%20al.%20%7C%20%3Ci%3ENutrients%3C%5C%2Fi%3E.%202021%3B13%283%29%3A735.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fnu13030735%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fnu13030735%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High-Dose%20Vitamin%20C%20in%20Advanced-Stage%20Cancer%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Zasowska-Nowak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piotr%20Jan%22%2C%22lastName%22%3A%22Nowak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleksandra%22%2C%22lastName%22%3A%22Cia%5Cu0142kowska-Rysz%22%7D%5D%2C%22abstractNote%22%3A%22High-dose%20intravenously%20administered%20vitamin%20C%20%28IVC%29%20is%20widely%20used%20in%20cancer%20patients%20by%20complementary%20and%20alternative%20medicine%20practitioners.%20The%20most%20frequent%20indications%20for%20IVC%20therapy%20result%20from%20the%20belief%20in%20its%20effectiveness%20as%20a%20potent%20anti-cancer%20agent%20which%20additionally%20enhances%20chemosensitivity%20of%20cancer%20cells%20and%20reduces%20chemotherapy-related%20toxicities%20and%20fatigue%20intensity.%20In%20this%20narrative%20review%2C%20we%20decided%20to%20deal%20with%20this%20issue%2C%20trying%20to%20answer%20the%20question%20whether%20there%20is%20any%20scientific%20evidence%20supporting%20the%20rationale%20for%20application%20of%20high-dose%20IVC%20therapy%20in%20advanced-stage%20cancer%20patients.%20Although%20results%20obtained%20from%20preclinical%20studies%20demonstrated%20that%20millimolar%20ascorbate%20plasma%20concentrations%20achievable%20only%20after%20IVC%20administration%20were%20cytotoxic%20to%20fast-growing%20malignant%20cells%20and%20inhibited%20tumor%20growth%20as%20well%20as%20prolonged%20the%20survival%20of%20laboratory%20animals%2C%20such%20positive%20effects%20were%20not%20found%20in%20human%20studies%20with%20advanced-stage%20cancer%20patients.%20We%20also%20have%20not%20found%20the%20rationale%20for%20the%20use%20of%20IVC%20to%20increase%20the%20effectiveness%20of%20chemotherapy%20and%20to%20reduce%20the%20chemotherapy-induced%20toxicity%20in%20the%20above%20mentioned%20group.%20Nevertheless%2C%20in%20palliative%20care%2C%20high-dose%20IVC%20might%20be%20considered%20as%20a%20therapy%20improving%20the%20quality%20of%20life%20and%20reducing%20cancer-related%20symptoms%2C%20such%20as%20fatigue%20and%20bone%20pain.%20However%2C%20because%20of%20the%20absence%20of%20placebo-controlled%20randomized%20trials%20on%20IVC%20efficacy%20in%20advanced-stage%20cancer%20patients%2C%20the%20placebo%20effect%20cannot%20be%20excluded.%22%2C%22date%22%3A%222021-2-26%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fnu13030735%22%2C%22ISSN%22%3A%222072-6643%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC7996511%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22L6EM8LL5%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ou%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-17%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EA%20randomized%20phase%20II%20trial%20of%20best%20supportive%20care%20with%20or%20without%20hyperthermia%20and%20vitamin%20C%20for%20heavily%20pretreated%2C%20advanced%2C%20refractory%20non-small-cell%20lung%20cancer%3C%5C%2Fb%3E%23%23%212020%20%7C%20Ou%20J%2C%20Zhu%20X%2C%20et%20al.%20%7C%20%3Ci%3EJ%20Adv%20Res%3C%5C%2Fi%3E.%202020%3B24%3A175-182.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jare.2020.03.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jare.2020.03.004%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20randomized%20phase%20II%20trial%20of%20best%20supportive%20care%20with%20or%20without%20hyperthermia%20and%20vitamin%20C%20for%20heavily%20pretreated%2C%20advanced%2C%20refractory%20non-small-cell%20lung%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junwen%22%2C%22lastName%22%3A%22Ou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xinyu%22%2C%22lastName%22%3A%22Zhu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengfei%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanping%22%2C%22lastName%22%3A%22Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yimin%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiufan%22%2C%22lastName%22%3A%22Peng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuang%22%2C%22lastName%22%3A%22Bao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junhua%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xinting%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tao%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clifford%20L.K.%22%2C%22lastName%22%3A%22Pang%22%7D%5D%2C%22abstractNote%22%3A%22Our%20previous%20study%20indicated%20that%20intravenous%20vitamin%20C%20%28IVC%29%20treatment%20concurrent%20with%20modulated%20electrohyperthermia%20%28mEHT%29%20was%20safe%20and%20improved%20the%20quality%20of%20life%20%28QoL%29%20of%20non-small-cell%20lung%20cancer%20%28NSCLC%29%20patients.%20The%20aim%20of%20this%20trial%20was%20to%20further%20verify%20the%20efficacy%20of%20the%20above%20combination%20therapy%20in%20previously%20treated%20patients%20with%20refractory%20advanced%20%28stage%20IIIb%20or%20IV%29%20NSCLC.%20A%20total%20of%2097%20patients%20were%20randomized%20to%20receive%20IVC%5Cu00a0and%20mEHT%5Cu00a0plus%5Cu00a0best%20supportive%20care%20%28BSC%29%20%28n%5Cu00a0%3D%5Cu00a049%20in%20the%20active%20arm%2C%20receiving%201%5Cu00a0g%5C%2Fkg%5Cu00a0%2A%5Cu00a0d%20IVC%20concurrently%20with%20mEHT%2C%20three%20times%20a%20week%20for%2025%20treatments%20in%20total%29%20or%20BSC%20alone%20%28n%5Cu00a0%3D%5Cu00a048%20in%20the%20control%20arm%29.%20After%20a%20median%20follow-up%20of%2024%5Cu00a0months%2C%20progression-free%20survival%20%28PFS%29%20and%20overall%20survival%20%28OS%29%20were%20significantly%20prolonged%20by%20combination%20therapy%20compared%20to%20BSC%20alone%20%28PFS%3A%203%5Cu00a0months%20vs%201.85%5Cu00a0months%2C%20P%5Cu00a0%3C%5Cu00a00.05%3B%20OS%3A%209.4%5Cu00a0months%20vs%205.6%5Cu00a0months%2C%20P%5Cu00a0%3C%5Cu00a00.05%29.%20QoL%20was%20significantly%20increased%20in%20the%20active%20arm%20despite%20the%20advanced%20stage%20of%20disease.%20The%203-month%20disease%20control%20rate%20after%20treatment%20was%2042.9%25%20in%20the%20active%20arm%20and%2016.7%25%20in%20the%20control%20arm%20%28P%5Cu00a0%3C%5Cu00a00.05%29.%20Overall%2C%20IVC%5Cu00a0and%20mEHT%20may%20have%20the%20ability%20to%20improve%20the%20prognosis%20of%20patients%20with%20advanced%20NSCLC.%22%2C%22date%22%3A%222020-3-17%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jare.2020.03.004%22%2C%22ISSN%22%3A%222090-1232%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC7190757%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22XURFAKIH%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gillberg%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-17%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EOral%20vitamin%20C%20supplementation%20to%20patients%20with%20myeloid%20cancer%20on%20azacitidine%20treatment%3A%20Normalization%20of%20plasma%20vitamin%20C%20induces%20epigenetic%20changes%3C%5C%2Fb%3E%23%23%212019%20%7C%20Gillberg%20L%2C%20%26%23xD8%3Brskov%20AD%2C%20et%20al.%20%7C%20%3Ci%3EClin%20Epigenetics%3C%5C%2Fi%3E.%202019%3B11%3A143.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13148-019-0739-5%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13148-019-0739-5%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Oral%20vitamin%20C%20supplementation%20to%20patients%20with%20myeloid%20cancer%20on%20azacitidine%20treatment%3A%20Normalization%20of%20plasma%20vitamin%20C%20induces%20epigenetic%20changes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linn%22%2C%22lastName%22%3A%22Gillberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22%5Cu00d8rskov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ammar%22%2C%22lastName%22%3A%22Nasif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hitoshi%22%2C%22lastName%22%3A%22Ohtani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%22%2C%22lastName%22%3A%22Madaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakob%20W.%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Rapin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanne%20B.%22%2C%22lastName%22%3A%22Mogensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minmin%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inge%20H.%22%2C%22lastName%22%3A%22Dufva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%22%2C%22lastName%22%3A%22Lykkesfeldt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petra%22%2C%22lastName%22%3A%22Hajkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20A.%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kirsten%22%2C%22lastName%22%3A%22Gr%5Cu00f8nb%5Cu00e6k%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnPatients%20with%5Cu00a0haematological%20malignancies%20are%20often%20vitamin%20C%20deficient%2C%20and%20vitamin%20C%20is%20essential%20for%20the%20TET-induced%20conversion%20of%205-methylcytosine%20%285mC%29%20to%205-hydroxymethylcytosine%20%285hmC%29%2C%20the%20first%20step%20in%20active%20DNA%20demethylation.%20Here%2C%20we%20investigate%20whether%20oral%20vitamin%20C%20supplementation%20can%20correct%20vitamin%20C%20deficiency%20and%20affect%20the%205hmC%5C%2F5mC%20ratio%20in%20patients%20with%5Cu00a0myeloid%20cancers%20treated%20with%20DNA%20methyltransferase%20inhibitors%20%28DNMTis%29.%5Cn%5CnResults%5CnWe%20conducted%20a%20randomized%2C%20double-blinded%2C%20placebo-controlled%20pilot%20trial%20%28NCT02877277%29%20in%20Danish%20patients%20with%5Cu00a0myeloid%20cancers%20performed%20during%203%5Cu2009cycles%20of%20DNMTi-treatment%20%285-azacytidine%2C%20100%5Cu2009mg%5C%2Fm2%5C%2Fd%20for%205%5Cu2009days%20in%2028-day%5Cu2009cycles%29%20supplemented%20by%20oral%20dose%20of%20500%5Cu2009mg%20vitamin%20C%20%28n%5Cu2009%3D%5Cu200910%29%20or%20placebo%20%28n%5Cu2009%3D%5Cu200910%29%20daily%20during%20the%20last%202%5Cu2009cycles.%20Fourteen%20patients%20%2870%25%29%20were%20deficient%20in%20plasma%20vitamin%20C%20%28%3C%5Cu200923%5Cu2009%5Cu03bcM%29%20and%20four%20of%20the%20remaining%20six%20patients%20were%20taking%20vitamin%20supplements%20at%20inclusion.%20Global%20DNA%20methylation%20was%20significantly%20higher%20in%20patients%20with%20severe%20vitamin%20C%20deficiency%20%28%3C%5Cu200911.4%5Cu2009%5Cu03bcM%3B%204.997%20vs%204.656%25%205mC%20relative%20to%20deoxyguanosine%2C%2095%25%20CI%20%5B0.126%2C%200.556%5D%2C%20P%5Cu2009%3D%5Cu20090.004%29.%20Oral%20supplementation%20restored%20plasma%20vitamin%20C%20levels%20to%20the%20normal%20range%20in%20all%20patients%20in%20the%20vitamin%20C%20arm%20%28mean%20increase%2034.85%5Cu2009%5Cu00b1%5Cu20097.94%5Cu2009%5Cu03bcM%2C%20P%5Cu2009%3D%5Cu20090.0004%29.%20We%20show%20for%20the%20first%20time%20that%20global%205hmC%5C%2F5mC%20levels%20were%20significantly%20increased%20in%20mononuclear%20myeloid%20cells%20from%20patients%20receiving%20oral%20vitamin%20C%20compared%20to%20placebo%20%280.037%25%20vs%20%5Cu2212%5Cu20090.029%25%2C%2095%25%20CI%20%5B%5Cu2212%5Cu20090.129%2C%20%5Cu2212%5Cu20090.003%5D%2C%20P%5Cu2009%3D%5Cu20090.041%29.%5Cn%5CnConclusions%5CnNormalization%20of%20plasma%20vitamin%20C%20by%20oral%20supplementation%20leads%20to%20an%20increase%20in%20the%205hmC%5C%2F5mC%20ratio%20compared%20to%20placebo-treated%20patients%20and%20may%20enhance%20the%20biological%20effects%20of%20DNMTis.%20The%20clinical%20efficacy%20of%20oral%20vitamin%20C%20supplementation%20to%20DNMTis%20should%20be%20investigated%20in%20a%20large%20randomized%2C%20placebo-controlled%20clinical%20trial.%5Cn%5CnTrial%20registration%5CnClinicalTrials.gov%2C%20NCT02877277.%20Registered%20on%209%20August%202016%2C%20retrospectively%20registered.%22%2C%22date%22%3A%222019-10-17%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13148-019-0739-5%22%2C%22ISSN%22%3A%221868-7075%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC6798470%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-19T13%3A37%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22AMKPX322%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Das%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EClinical%20remission%20following%20ascorbate%20treatment%20in%20a%20case%20of%20acute%20myeloid%20leukemia%20with%20mutations%20in%20TET2%20and%20WT1%3C%5C%2Fb%3E%23%23%212019%20%7C%20Das%20AB%2C%20Kakadia%20PM%2C%20et%20al.%20%7C%20%3Ci%3EBlood%20Cancer%20J%3C%5C%2Fi%3E.%202019%3B9%2810%29%3A82.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41408-019-0242-4%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41408-019-0242-4%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20remission%20following%20ascorbate%20treatment%20in%20a%20case%20of%20acute%20myeloid%20leukemia%20with%20mutations%20in%20TET2%20and%20WT1%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Das%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Purvi%20M.%22%2C%22lastName%22%3A%22Kakadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damian%22%2C%22lastName%22%3A%22Wojcik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucy%22%2C%22lastName%22%3A%22Pemberton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20J.%22%2C%22lastName%22%3A%22Browett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20K.%22%2C%22lastName%22%3A%22Bohlander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margreet%20C.%20M.%22%2C%22lastName%22%3A%22Vissers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-10-2%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41408-019-0242-4%22%2C%22ISSN%22%3A%222044-5385%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC6775073%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-19T13%3A34%3A29Z%22%7D%7D%2C%7B%22key%22%3A%227IHDPJW4%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ang%20et%20al.%22%2C%22parsedDate%22%3A%222018-10-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EVitamin%20C%20and%20immune%20cell%20function%20in%20inflammation%20and%20cancer%3C%5C%2Fb%3E%23%23%212018%20%7C%20Ang%20A%2C%20Pullar%20JM%2C%20et%20al.%20%7C%20%3Ci%3EBiochem%20Soc%20Trans%3C%5C%2Fi%3E.%202018%3B46%285%29%3A1147-1159.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1042%5C%2FBST20180169%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1042%5C%2FBST20180169%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Vitamin%20C%20and%20immune%20cell%20function%20in%20inflammation%20and%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abel%22%2C%22lastName%22%3A%22Ang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliet%20M.%22%2C%22lastName%22%3A%22Pullar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%20J.%22%2C%22lastName%22%3A%22Currie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margreet%20C.M.%22%2C%22lastName%22%3A%22Vissers%22%7D%5D%2C%22abstractNote%22%3A%22Vitamin%20C%20%28ascorbate%29%20is%20maintained%20at%20high%20levels%20in%20most%20immune%20cells%20and%20can%20affect%20many%20aspects%20of%20the%20immune%20response.%20Intracellular%20levels%20generally%20respond%20to%20variations%20in%20plasma%20ascorbate%20availability%2C%20and%20a%20combination%20of%20inadequate%20intake%20and%20increased%20turnover%20during%20severe%20stress%20can%20result%20in%20low%20plasma%20ascorbate%20status.%20Intracellular%20ascorbate%20supports%20essential%20functions%20and%2C%20in%20particular%2C%20acts%20as%20an%20enzyme%20cofactor%20for%20Fe-%20or%20Cu-containing%20oxygenases.%20Newly%20discovered%20enzymes%20in%20this%20family%20regulate%20cell%20metabolism%20and%20epigenetics%2C%20and%20dysregulation%20of%20their%20activity%20can%20affect%20cell%20phenotype%2C%20growth%20and%20survival%20pathways%2C%20and%20stem%20cell%20phenotype.%20This%20brief%20overview%20details%20some%20of%20the%20recent%20advances%20in%20our%20understanding%20of%20how%20ascorbate%20availability%20can%20affect%20the%20hydroxylases%20controlling%20the%20hypoxic%20response%20and%20the%20DNA%20and%20histone%20demethylases.%20These%20processes%20play%20important%20roles%20in%20the%20regulation%20of%20the%20immune%20system%2C%20altering%20cell%20survival%20pathways%2C%20metabolism%20and%20functions.%22%2C%22date%22%3A%222018-10-19%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1042%5C%2FBST20180169%22%2C%22ISSN%22%3A%220300-5127%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC6195639%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%226V2ECJQI%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Starczak%20et%20al.%22%2C%22parsedDate%22%3A%222018-07-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EIn%20vivo%20evidence%20of%20ascorbate%20involvement%20in%20the%20generation%20of%20epigenetic%20DNA%20modifications%20in%20leukocytes%20from%20patients%20with%20colorectal%20carcinoma%2C%20benign%20adenoma%20and%20inflammatory%20bowel%20disease%3C%5C%2Fb%3E%23%23%212018%20%7C%20Starczak%20M%2C%20Zarakowska%20E%2C%20et%20al.%20%7C%20%3Ci%3EJ%20Transl%20Med%3C%5C%2Fi%3E.%202018%3B16%3A204.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12967-018-1581-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12967-018-1581-9%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22In%20vivo%20evidence%20of%20ascorbate%20involvement%20in%20the%20generation%20of%20epigenetic%20DNA%20modifications%20in%20leukocytes%20from%20patients%20with%20colorectal%20carcinoma%2C%20benign%20adenoma%20and%20inflammatory%20bowel%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Starczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ewelina%22%2C%22lastName%22%3A%22Zarakowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martyna%22%2C%22lastName%22%3A%22Modrzejewska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Dziaman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Szpila%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kinga%22%2C%22lastName%22%3A%22Linowiecka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jolanta%22%2C%22lastName%22%3A%22Guz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justyna%22%2C%22lastName%22%3A%22Szpotan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maciej%22%2C%22lastName%22%3A%22Gawronski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Labejszo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariel%22%2C%22lastName%22%3A%22Liebert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zbigniew%22%2C%22lastName%22%3A%22Banaszkiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Klopocka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marek%22%2C%22lastName%22%3A%22Foksinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Gackowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryszard%22%2C%22lastName%22%3A%22Olinski%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnA%20characteristic%20feature%20of%20malignant%20cells%2C%20such%20as%20colorectal%20cancer%20cells%2C%20is%20a%20profound%20decrease%20in%20the%20level%20of%205-hydroxymethylcytosine%2C%20a%20product%20of%205-methylcytosine%20oxidation%20by%20TET%20enzymes.%20Recent%20studies%20showed%20that%20ascorbate%20may%20upregulate%20the%20activity%20of%20TET%20enzymes%20in%20cultured%20cells%20and%20enhance%20formation%20of%20their%20products%20in%20genomic%20DNA.%5Cn%5CnMethods%5CnThe%20study%20included%20four%20groups%20of%20subjects%3A%20healthy%20controls%20%28n%5Cu2009%3D%5Cu200979%29%2C%20patients%20with%20inflammatory%20bowel%20disease%20%28IBD%2C%20n%5Cu2009%3D%5Cu200951%29%2C%20adenomatous%20polyps%20%28n%5Cu2009%3D%5Cu200967%29%20and%20colorectal%20cancer%20%28n%5Cu2009%3D%5Cu2009136%29.%20The%20list%20of%20analyzed%20parameters%20included%20%28i%29%20leukocyte%20levels%20of%20epigenetic%20DNA%20modifications%20and%208-oxo-7%2C8-dihydro-2%5Cu2032-deoxyguanosine%2C%20a%20marker%20of%20oxidatively%20modified%20DNA%2C%20determined%20by%20means%20of%20isotope-dilution%20automated%20online%20two-dimensional%20ultra-performance%20liquid%20chromatography%20with%20tandem%20mass%20spectrometry%2C%20%28ii%29%20expression%20of%20TET%20mRNA%20measured%20with%20RT-qPCR%2C%20and%20%28iii%29%20chromatographically-determined%20plasma%20concentrations%20of%20retinol%2C%20alpha-tocopherol%20and%20ascorbate.%5Cn%5CnResults%5CnPatients%20from%20all%20groups%20presented%20with%20significantly%20lower%20levels%20of%205-methylcytosine%20and%205-hydroxymethylcytosine%20in%20DNA%20than%20the%20controls.%20A%20similar%20tendency%20was%20also%20observed%20for%205-hydroxymethyluracil%20level.%20Patients%20with%20IBD%20showed%20the%20highest%20levels%20of%205-formylcytosine%20and%208-oxo-7%2C8-dihydro-2%5Cu2032-deoxyguanosine%20of%20all%20study%20subjects%2C%20and%20individuals%20with%20colorectal%20cancer%20presented%20with%20the%20lowest%20concentrations%20of%20ascorbate%20and%20retinol.%20A%20positive%20correlation%20was%20observed%20between%20plasma%20concentration%20of%20ascorbate%20and%20levels%20of%20two%20epigenetic%20modifications%2C%205-hydroxymethylcytosine%20and%205-hydroxymethyluracil%20in%20leukocyte%20DNA.%20Moreover%2C%20a%20significant%20difference%20was%20found%20in%20the%20levels%20of%20these%20modifications%20in%20patients%20whose%20plasma%20concentrations%20of%20ascorbate%20were%20below%20the%20lower%20and%20above%20the%20upper%20quartile%20for%20the%20control%20group.%5Cn%5CnConclusions%5CnThese%20findings%20suggest%20that%20deficiency%20of%20ascorbate%20in%20the%20blood%20may%20be%20a%20marker%20of%20its%20shortage%20in%20other%20tissues%2C%20which%20in%20turn%20may%20correspond%20to%20deterioration%20of%20DNA%20methylation-demethylation.%20These%20observations%20may%20provide%20a%20rationale%20for%20further%20research%20on%20blood%20biomarkers%20of%20colorectal%20cancer%20development.%5Cn%5CnElectronic%20supplementary%20material%5CnThe%20online%20version%20of%20this%20article%20%2810.1186%5C%2Fs12967-018-1581-9%29%20contains%20supplementary%20material%2C%20which%20is%20available%20to%20authorized%20users.%22%2C%22date%22%3A%222018-7-20%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12967-018-1581-9%22%2C%22ISSN%22%3A%221479-5876%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC6053776%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T20%3A22%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22H5TVZ2PB%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carr%22%2C%22parsedDate%22%3A%222017-11-21%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3ESymposium%20on%20Vitamin%20C%3C%5C%2Fb%3E%23%23%212017%20%7C%20Carr%20AC.%20%7C%20%3Ci%3EAntioxidants%20%28Basel%29%3C%5C%2Fi%3E.%202017%3B6%284%29%3A94.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantiox6040094%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantiox6040094%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Symposium%20on%20Vitamin%20C%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anitra%20C.%22%2C%22lastName%22%3A%22Carr%22%7D%5D%2C%22abstractNote%22%3A%22Symposium%20on%20Vitamin%20C%2C%2015th%20September%202017%3B%20Part%20of%20the%20Linus%20Pauling%20Institute%5Cu2019s%209th%20International%20Conference%20on%20Diet%20and%20Optimum%20Health%22%2C%22date%22%3A%222017-11-21%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fantiox6040094%22%2C%22ISSN%22%3A%222076-3921%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC5745504%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-19T22%3A09%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22IPS7JY5N%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Frei%20et%20al.%22%2C%22parsedDate%22%3A%222012-09-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EAuthors%26%23x2019%3B%20Perspective%3A%20What%20is%20the%20Optimum%20Intake%20of%20Vitamin%20C%20in%20Humans%3F%3C%5C%2Fb%3E%23%23%212012%20%7C%20Frei%20B%2C%20Birlouez-Aragon%20I%2C%20et%20al.%20%7C%20%3Ci%3ECritical%20Reviews%20in%20Food%20Science%20and%20Nutrition%3C%5C%2Fi%3E.%202012%3B52%289%29%3A815-829.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10408398.2011.649149%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10408398.2011.649149%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Authors%27%20Perspective%3A%20What%20is%20the%20Optimum%20Intake%20of%20Vitamin%20C%20in%20Humans%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Balz%22%2C%22lastName%22%3A%22Frei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Birlouez-Aragon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%22%2C%22lastName%22%3A%22Lykkesfeldt%22%7D%5D%2C%22abstractNote%22%3A%22The%20recommended%20dietary%20allowance%20%28RDA%29%20of%20vitamin%20C%20has%20traditionally%20been%20based%20on%20the%20prevention%20of%20the%20vitamin%20C%20deficiency%20disease%2C%20scurvy.%20While%20higher%20intakes%20of%20vitamin%20C%20may%20exert%20additional%20health%20benefits%2C%20the%20limited%20Phase%20III%20randomized%20placebo-controlled%20trials%20%28RCTs%29%20of%20vitamin%20C%20supplementation%20have%20not%20found%20consistent%20benefit%20with%20respect%20to%20chronic%20disease%20prevention.%20To%20date%2C%20this%20has%20precluded%20upward%20adjustments%20of%20the%20current%20RDA.%20Here%20we%20argue%20that%20Phase%20III%20RCTs%5Cu2014designed%20principally%20to%20test%20the%20safety%20and%20efficacy%20of%20pharmaceutical%20drugs%5Cu2014are%20ill%20suited%20to%20assess%20the%20health%20benefits%20of%20essential%20nutrients%3B%20and%20the%20currently%20available%20scientific%20evidence%20is%20sufficient%20to%20determine%20the%20optimum%20intake%20of%20vitamin%20C%20in%20humans.%20This%20evidence%20establishes%20biological%20plausibility%20and%20mechanisms%20of%20action%20for%20vitamin%20C%20in%20the%20primary%20prevention%20of%20coronary%20heart%20disease%2C%20stroke%2C%20and%20cancer%3B%20and%20is%20buttressed%20by%20consistent%20data%20from%20prospective%20cohort%20studies%20based%20on%20blood%20analysis%20or%20dietary%20intake%20and%20well-designed%20Phase%20II%20RCTs.%20These%20RCTs%20show%20that%20vitamin%20C%20supplementation%20lowers%20hypertension%2C%20endothelial%20dysfunction%2C%20chronic%20inflammation%2C%20and%20Helicobacter%20pylori%20infection%2C%20which%20are%20independent%20risk%20factors%20of%20cardiovascular%20diseases%20and%20certain%20cancers.%20Furthermore%2C%20vitamin%20C%20acts%20as%20a%20biological%20antioxidant%20that%20can%20lower%20elevated%20levels%20of%20oxidative%20stress%2C%20which%20also%20may%20contribute%20to%20chronic%20disease%20prevention.%20Based%20on%20the%20combined%20evidence%20from%20human%20metabolic%2C%20pharmacokinetic%2C%20and%20observational%20studies%20and%20Phase%20II%20RCTs%2C%20we%20conclude%20that%20200%20mg%20per%20day%20is%20the%20optimum%20dietary%20intake%20of%20vitamin%20C%20for%20the%20majority%20of%20the%20adult%20population%20to%20maximize%20the%20vitamin%27s%20potential%20health%20benefits%20with%20the%20least%20risk%20of%20inadequacy%20or%20adverse%20health%20effects.%22%2C%22date%22%3A%222012-09-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F10408398.2011.649149%22%2C%22ISSN%22%3A%221040-8398%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10408398.2011.649149%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22BBRQSU3S%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gonzalez%20et%20al.%22%2C%22parsedDate%22%3A%222012-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3ESchedule%20Dependence%20in%20Cancer%20Therapy%3A%20Intravenous%20Vitamin%20C%20and%20the%20Systemic%20Saturation%20Hypothesis%3C%5C%2Fb%3E%23%23%212012%20%7C%20Gonzalez%20MJ%2C%20Miranda%20Massari%20JR%2C%20et%20al.%20%7C%20%3Ci%3EJ%20Orthomol%20Med%3C%5C%2Fi%3E.%202012%3B27%281%29%3A9-12.%20%23%23%21%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC4031610%5C%2F%27%3Ehttps%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC4031610%5C%2F%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Schedule%20Dependence%20in%20Cancer%20Therapy%3A%20Intravenous%20Vitamin%20C%20and%20the%20Systemic%20Saturation%20Hypothesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20R.%22%2C%22lastName%22%3A%22Miranda%20Massari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Duconge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%20H.%22%2C%22lastName%22%3A%22Riordan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Ichim%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20significant%20number%20of%20in%20vitro%20and%20in%20vivo%20studies%20to%20assess%20vitamin%20C%20effects%20on%20cancer%20following%20the%20application%20of%20large%20doses%20and%20its%20extensive%20use%20by%20alternative%20medicine%20practitioners%20in%20the%20USA%3B%20the%20precise%20schedule%20for%20successful%20cancer%20therapy%20is%20still%20unknown.%20Based%20on%20interpretation%20of%20the%20available%20data%2C%20we%20postulate%20that%20the%20relationship%20between%20Vitamin%20C%20doses%20and%20plasma%20concentration%20x%20time%2C%20the%20capability%20of%20tissue%20stores%20upon%20distribution%2C%20and%20the%20saturable%20mechanism%20of%20urinary%20excretion%20are%20all%20important%20determinants%20to%20understand%20the%20physiology%20of%20high%20intravenous%20vitamin%20C%20dose%20administration%20and%20its%20effect%20on%20cancer.%20Practitioners%20should%20pay%20more%20attention%20to%20the%20cumulative%20vitamin%20C%20effect%20instead%20of%20the%20vitamin%20C%20concentrations%20to%20account%20for%20observed%20discrepancy%20in%20antitumor%20response.%20We%20suggest%20that%20multiple%2C%20intermittent%2C%20short-term%20intravenous%20infusions%20of%20vitamin%20C%20over%20a%20longer%20time%20period%20will%20correlate%20with%20greater%20antitumor%20effects%20than%20do%20single%20continuous%20IV%20doses%20of%20the%20same%20total%20exposure.%20This%20approach%20would%20be%20expected%20to%20minimize%20saturation%20of%20renal%20reabsorption%2C%20providing%20a%20continuous%20%5Cu201cdynamic%20flow%5Cu201d%20of%20vitamin%20C%20in%20the%20body%20for%20optimal%20systemic%20exposure%20and%20clinical%20outcomes.%20This%20prevents%20the%20%5Cu201csystemic%20saturation%5Cu201d%20phenomena%2C%20which%20may%20recycle%20vitamin%20C%20and%20render%20it%20less%20effective%20as%20an%20anticancer%20agent.%20Nonetheless%2C%20more%20pharmacokinetic%20and%20pharmacodynamic%20studies%20are%20needed%20to%20fully%20understand%20this%20schedule-dependence%20phenomenon.%22%2C%22date%22%3A%222012-1-1%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220834-4825%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC4031610%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22MARRI8IN%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Coulter%20et%20al.%22%2C%22parsedDate%22%3A%222003-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3E%3Ci%3EEffect%20of%20the%20Supplemental%20Use%20of%20Antioxidants%20Vitamin%20C%2C%20Vitamin%20E%2C%20and%20Coenzyme%20Q10%20for%20the%20Prevention%20and%20Treatment%20of%20Cancer%3C%5C%2Fi%3E%3C%5C%2Fb%3E%23%23%212003%20%7C%20Coulter%20I%2C%20Hardy%20M%2C%20et%20al.%20%7C%20Agency%20for%20Healthcare%20Research%20and%20Quality%20%28US%29%3B%202003.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22book%22%2C%22title%22%3A%22Effect%20of%20the%20Supplemental%20Use%20of%20Antioxidants%20Vitamin%20C%2C%20Vitamin%20E%2C%20and%20Coenzyme%20Q10%20for%20the%20Prevention%20and%20Treatment%20of%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%22%2C%22lastName%22%3A%22Hardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Shekelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally%20C.%22%2C%22lastName%22%3A%22Morton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%22%2C%22lastName%22%3A%22Udani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myles%22%2C%22lastName%22%3A%22Spar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Oda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20K.%22%2C%22lastName%22%3A%22Jungvig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wenli%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberta%22%2C%22lastName%22%3A%22Shanman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sydne%22%2C%22lastName%22%3A%22Newberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%20R.%22%2C%22lastName%22%3A%22Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Di%22%2C%22lastName%22%3A%22Valentine%22%7D%5D%2C%22abstractNote%22%3A%22Structured%20AbstractObjectives%3AThe%20objective%20of%20this%20report%20was%20to%20conduct%20a%20comprehensive%20literature%20review%20and%20synthesis%20of%20evidence%20on%20the%20use%20of%20the%20supplements%20vitamin%20C%2C%20vitamin%20E%2C%20and%20coenzyme%20Q10%20for%20the%20treatment%20and%20prevention%20of%20cancer.Search%20Strategy%3AWe%20performed%20a%20search%20of%2013%20databases%20through%20early%202001%20using%20the%20terms%20coenzyme%20Q10%2C%20vitamin%20C%2C%20and%20vitamin%20E%20and%20their%20many%20pharmacological%20synonyms.%20The%20bibliographies%20of%20review%20articles%20were%20also%20searched%2C%20and%20experts%20were%20questioned%20to%20identify%20additional%20citations.Selection%20Criteria%3AReports%20were%20included%20in%20the%20synthesis%20of%20evidence%20if%20they%20focused%20on%20the%20use%20of%20supplements%20of%20coenzyme%20Q10%2C%20vitamin%20C%2C%20or%20vitamin%20E%20for%20the%20prevention%20and%20treatment%20of%20cancer%20and%20presented%20the%20results%20of%20clinical%20trials%20on%20human%20subjects.%20Language%20of%20publication%20was%20not%20a%20barrier%20to%20inclusion.Data%20Collection%20and%20Analysis%3AAll%20selected%20titles%2C%20abstracts%2C%20and%20articles%2C%20in%20all%20languages%2C%20were%20reviewed%20independently%20by%20two%20reviewers%20fluent%20in%20the%20appropriate%20language.%20Information%20was%20collected%20about%20patient%20demographics%2C%20disease%20state%2C%20intervention%2C%20study%20design%2C%20and%20outcomes.%20We%20focused%20on%20three%20primary%20outcomes%3A%20death%2C%20development%20of%20new%20tumors%2C%20and%20effect%20on%20colonic%20polyps.%20For%20deaths%20and%20new%20tumors%2C%20the%20trials%20were%20too%20heterogeneous%20to%20pool%20for%20meta-analyses.%20For%20colonic%20polyps%2C%20the%20trials%20were%20sufficiently%20homogeneous%20to%20support%20a%20meta-analysis.We%20also%20identified%20a%20group%20of%20trials%20with%20intermediate%20outcomes%2C%20and%20these%20were%20reviewed%20in%20a%20qualitative%20analysis.Main%20Results%3AWe%20identified%20432%20articles%20for%20screening%20from%20which%2035%20articles%20met%20the%20criteria%20for%20inclusion%20in%20the%20analysis.%20These%20articles%20represented%2037%20unique%20studies%20and%2022%20unique%20trials%2C%20because%20many%20studies%20presented%20data%20on%20the%20same%20trial.%20The%20identified%20trials%20varied%20greatly%20in%20quality.%20For%20the%20doses%20and%20populations%20studied%20in%20the%20trials.There%20was%20no%20evidence%20found%20for%20assessing%20the%20efficacy%20of%20coenzyme%20Q10%20for%20prevention%20or%20treatment%20of%20cancer.We%20identified%20three%20large%20trials%20assessing%20the%20effect%20of%20vitamin%20C%20and%20vitamin%20E%20in%20various%20combinations%20given%20to%20persons%20without%20cancer.%20No%20trial%20reported%20a%20statistically%20significant%20beneficial%20effect%20on%20death%20due%20to%20cancer.%20Subgroup%20analysis%20did%20identify%20a%20statistically%20significant%209%25%20reduction%20in%20all%20cause%20mortality%20and%20a%20borderline%20significant%2013%25%20reduction%20in%20all-cancer%20mortality%20associated%20with%20supplemental%20vitamin%20E%20in%20combination%20with%20other%20micro-nutrients.%20All%20other%20trials%20showed%20no%20benefit%20for%20all%20other%20types%20of%20new%20tumor%20development%20except%20for%20one%20arm%20of%20the%20ATBC%20trial%2C%20which%20showed%20a%20decrease%20in%20the%20development%20of%20new%20prostate%20tumors.We%20identified%20seven%20trials%20that%20assessed%20the%20use%20of%20vitamin%20C%20in%20patients%20with%20advanced%20cancer.%20No%20trial%20reported%20a%20statistically%20significant%20mortality%20benefit.There%20was%20no%20decrease%20in%20risk%20of%20death%20for%20vitamin%20C%20as%20a%20treatment%20for%20advanced%20cancer.We%20identified%20six%20trials%20assessing%20the%20effect%20of%20combinations%20of%20vitamin%20C%20and%20vitamin%20E%20with%20and%20without%20beta-carotene%20on%20the%20development%20of%20colonic%20polyps.%20No%20trial%20reported%20a%20statistically%20significant%20beneficial%20effect.We%20identified%20six%20unique%20trials%20that%20reported%20on%20various%20intermediate%20outcomes.The%20following%20beneficial%20results%20were%20reported%20from%20single%20trials%3AVitamin%20C%20was%20found%20to%20be%20beneficial%20in%20reducing%20the%20occurrence%20of%20new%20tumors%20in%20a%20single%20trial%20of%20patients%20with%20bladder%20cancer%20also%20treated%20with%20bacillus%20Calmetee-Guerin%20%28BCG%29.Vitamin%20E%20in%20combination%20with%20omega-3%20fatty%20acid%20increases%20survival%20in%20patients%20severely%20ill%20with%20a%20variety%20of%20malignancies.A%20number%20of%20intermediate%20outcomes%20studies%20were%20positive.Conclusions%3AFor%20the%20interventions%20tested%2C%20in%20the%20populations%20described%2C%20there%20is%20scant%20evidence%20that%20vitamin%20C%20or%20vitamin%20E%20beneficially%20affects%20survival.%20Similarly%2C%20for%20the%20interventions%20tested%2C%20in%20the%20populations%20described%2C%20there%20are%20no%20results%20suggesting%20a%20benefit%20for%20the%20prevention%20of%20new%20tumors%2C%20which%20reach%20statistical%20significance%20with%20the%20exception%20of%20prostate%20cancer%20in%20subjects%20treated%20with%20alpha-tocopherol.%20One%20trial%20reported%20a%20benefit%20of%20a%20megadose%20vitamin%20therapy%20on%20the%20development%20of%20new%20tumors%20in%20patients%20with%20bladder%20cancer.%20However%2C%20the%20ability%20to%20infer%20from%20this%20finding%20is%20limited%20because%20the%20multi-component%20intervention%20limits%20our%20ability%20to%20attribute%20the%20reported%20efficacy%20to%20any%20particular%20component.For%20the%20outcome%20for%20colonic%20polyps%2C%20four%20trials%20focusing%20on%20secondary%20polyp%20recurrence%20could%20be%20pooled%20for%20analysis%20and%20none%20used%20vitamins%20C%20or%20E%20as%20a%20single%20intervention.%20The%20combination%20of%20vitamins%20C%20and%20E%20was%20not%20clinically%20superior%20to%20placebo%20in%20secondary%20prevention.%20The%20combination%20of%20vitamins%20C%20and%20E%20with%20beta-carotene%20or%20vitamin%20A%20did%20show%20a%20trend%20favoring%20a%20reduction%20in%20polyp%20recurrence%2C%20but%20this%20finding%20was%20not%20statistically%20significant.The%20systematic%20review%20of%20the%20literature%20does%20not%20support%20the%20hypothesis%20that%20the%20use%20of%20supplements%20of%20vitamin%20C%20or%20E%20or%20coenzyme%20Q10%20generally%20help%20prevent%20and%5C%2For%20treat%20cancer.%20There%20were%20isolated%20findings%20of%20benefit%2C%20which%20require%20confirmation.Future%20Research%3AFuture%20research%20should%20be%20done%20to%20confirm%20the%20positive%20findings%20from%20the%20single%20trials%20identified%20here.%20Investigation%20should%20be%20undertaken%20to%20understand%20the%20discrepancy%20between%20the%20epidemiologic%20evidence%20and%20the%20clinical%20trial%20data.%20Additional%20research%20should%20include%20population%20%28such%20as%20women%29%20not%20well%20studied.%22%2C%22date%22%3A%222003%20Aug%22%2C%22language%22%3A%22%22%2C%22ISBN%22%3A%22978-1-58763-091-0%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22T25BTRLX%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Moertel%20et%20al.%22%2C%22parsedDate%22%3A%221985-01-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EHigh-Dose%20Vitamin%20C%20versus%20Placebo%20in%20the%20Treatment%20of%20Patients%20with%20Advanced%20Cancer%20Who%20Have%20Had%20No%20Prior%20Chemotherapy%3C%5C%2Fb%3E%23%23%211985%20%7C%20Moertel%20CG%2C%20Fleming%20TR%2C%20et%20al.%20%7C%20%3Ci%3EN%20Engl%20J%20Med%3C%5C%2Fi%3E.%201985%3B312%283%29%3A137-141.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJM198501173120301%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJM198501173120301%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High-Dose%20Vitamin%20C%20versus%20Placebo%20in%20the%20Treatment%20of%20Patients%20with%20Advanced%20Cancer%20Who%20Have%20Had%20No%20Prior%20Chemotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20G.%22%2C%22lastName%22%3A%22Moertel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20R.%22%2C%22lastName%22%3A%22Fleming%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20T.%22%2C%22lastName%22%3A%22Creagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Rubin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22O%27Connell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20M.%22%2C%22lastName%22%3A%22Ames%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%221985-01-17%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJM198501173120301%22%2C%22ISSN%22%3A%220028-4793%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nejm.org%5C%2Fdoi%5C%2F10.1056%5C%2FNEJM198501173120301%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%229IDGQVY7%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cameron%20and%20Pauling%22%2C%22parsedDate%22%3A%221976-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3ESupplemental%20ascorbate%20in%20the%20supportive%20treatment%20of%20cancer%3A%20Prolongation%20of%20survival%20times%20in%20terminal%20human%20cancer.%3C%5C%2Fb%3E%23%23%211976%20%7C%20Cameron%20E%2C%20Pauling%20L.%20%7C%20%3Ci%3EProc%20Natl%20Acad%20Sci%20U%20S%20A%3C%5C%2Fi%3E.%201976%3B73%2810%29%3A3685-3689.%20%23%23%21%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC431183%5C%2F%27%3Ehttps%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC431183%5C%2F%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Supplemental%20ascorbate%20in%20the%20supportive%20treatment%20of%20cancer%3A%20Prolongation%20of%20survival%20times%20in%20terminal%20human%20cancer.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Cameron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Pauling%22%7D%5D%2C%22abstractNote%22%3A%22Ascorbic%20acid%20metabolism%20is%20associated%20with%20a%20number%20of%20mechanisms%20known%20to%20be%20involved%20in%20host%20resistance%20to%20malignant%20disease.%20Cancer%20patients%20are%20significantly%20depleted%20of%20ascorbic%20acid%2C%20and%20in%20our%20opinion%20this%20demonstrable%20biochemical%20characteristic%20indicates%20a%20substantially%20increased%20requirement%20and%20utilization%20of%20this%20substance%20to%20potentiate%20these%20various%20host%20resistance%20factors.%20The%20results%20of%20a%20clinical%20trial%20are%20presented%20in%20which%20100%20terminal%20cancer%20patients%20were%20given%20supplemental%20ascorbate%20as%20part%20of%20their%20routine%20management.%20Their%20progress%20is%20compared%20to%20that%20%20of%201000%20similar%20patients%20treated%20identically%2C%20but%20who%20received%20no%20supplemental%20ascorbate.%20The%20mean%20survival%20time%20is%20more%20than%204.2%20times%20as%20great%20for%20the%20ascorbate%20subjects%20%28more%20than%20210%20days%29%20as%20for%20the%20controls%20%2850%20days%29.%20Analysis%20of%20the%20survival-time%20curves%20indicates%20that%20deaths%20occur%20for%20about%2090%25%20of%20the%20ascorbate-treated%20patients%20at%20one-third%20the%20rate%20for%20the%20controls%20and%20that%20the%20other%2010%25%20have%20a%20much%20greater%20survival%20time%2C%20averaging%20more%20than%2020%20times%20that%20for%20the%20controls.%20The%20results%20clearly%20indicate%20that%20this%20simple%20and%20safe%20form%20of%20medication%20is%20of%20definite%20value%20in%20the%20treatment%20of%20patients%20with%20acvanced%20cancer.%22%2C%22date%22%3A%221976-10%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220027-8424%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC431183%5C%2F%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22EVF8TYLS%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cameron%20and%20Campbell%22%2C%22parsedDate%22%3A%221974-10-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EThe%20orthomolecular%20treatment%20of%20cancer%20II.%20Clinical%20trial%20of%20high-dose%20ascorbic%20acid%20supplements%20in%20advanced%20human%20cancer%3C%5C%2Fb%3E%23%23%211974%20%7C%20Cameron%20E%2C%20Campbell%20A.%20%7C%20%3Ci%3EChemico-Biological%20Interactions%3C%5C%2Fi%3E.%201974%3B9%284%29%3A285-315.%20%23%23%21%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2F0009-2797%2874%2990019-2%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2F0009-2797%2874%2990019-2%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20orthomolecular%20treatment%20of%20cancer%20II.%20Clinical%20trial%20of%20high-dose%20ascorbic%20acid%20supplements%20in%20advanced%20human%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ewan%22%2C%22lastName%22%3A%22Cameron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allan%22%2C%22lastName%22%3A%22Campbell%22%7D%5D%2C%22abstractNote%22%3A%22This%20communication%20reports%20the%20clinical%20response%20of%20fifty%20consecutive%20advanced%20cancer%20patients%20to%20the%20continuous%20administration%20of%20large%20doses%20of%20ascorbic%20acid.%20It%20concludes%20that%20this%20simple%20and%20safe%20form%20of%20medication%20is%20of%20definite%20value%20in%20the%20palliation%20of%20terminal%20cancer.%20The%20findings%20suggest%20that%20it%20should%20be%20employed%20as%20a%20standard%20supportive%20measure%20to%20reinforce%20established%20methods%20of%20treatment%20in%20the%20general%20management%20of%20earlier%20and%20more%20favorable%20cases.%22%2C%22date%22%3A%221974-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2F0009-2797%2874%2990019-2%22%2C%22ISSN%22%3A%220009-2797%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2F0009279774900192%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22NUEMCG29%22%2C%22library%22%3A%7B%22id%22%3A10725819%7D%2C%22meta%22%3A%7B%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cb%3EVitamin%20C%20Pharmacokinetics%3A%20Implications%20for%20Oral%20and%20Intravenous%20Use%20%7C%20Annals%20of%20Internal%20Medicine%3C%5C%2Fb%3E%23%23%21%3Cb%3EVitamin%20C%20Pharmacokinetics%3A%20Implications%20for%20Oral%20and%20Intravenous%20Use%20%7C%20Annals%20of%20Internal%20Medicine%3C%5C%2Fb%3E.%20%7C%20%23%23%21%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.acpjournals.org%5C%2Fdoi%5C%2Ffull%5C%2F10.7326%5C%2F0003-4819-140-7-200404060-00010%3Frfr_dat%3Dcr_pub%2B%2B0pubmed%26url_ver%3DZ39.88-2003%26rfr_id%3Dori%253Arid%253Acrossref.org%27%3Ehttps%3A%5C%2F%5C%2Fwww.acpjournals.org%5C%2Fdoi%5C%2Ffull%5C%2F10.7326%5C%2F0003-4819-140-7-200404060-00010%3Frfr_dat%3Dcr_pub%2B%2B0pubmed%26url_ver%3DZ39.88-2003%26rfr_id%3Dori%253Arid%253Acrossref.org%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Vitamin%20C%20Pharmacokinetics%3A%20Implications%20for%20Oral%20and%20Intravenous%20Use%20%7C%20Annals%20of%20Internal%20Medicine%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.acpjournals.org%5C%2Fdoi%5C%2Ffull%5C%2F10.7326%5C%2F0003-4819-140-7-200404060-00010%3Frfr_dat%3Dcr_pub%2B%2B0pubmed%26url_ver%3DZ39.88-2003%26rfr_id%3Dori%253Arid%253Acrossref.org%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%22VFY3LYPC%22%5D%2C%22dateModified%22%3A%222023-01-12T18%3A26%3A16Z%22%7D%7D%5D%7D
Pharmacological vitamin C inhibits mTOR signaling and tumor growth by degrading Rictor and inducing HMOX1 expression##!2023 | Qin S, Wang G, et al. | PLOS Genetics. 2023;19(2):e1010629. ##!http://doi.org/10.1371/journal.pgen.1010629
Ascorbate oxidase-like nanozyme with high specificity for inhibition of cancer cell proliferation and online electrochemical DOPAC monitoring##!2023 | Zhe Y, Wang J, et al. | Biosensors and Bioelectronics. 2023;220:114893. ##!http://doi.org/10.1016/j.bios.2022.114893
The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth##!2022 | Begimbetova D, Kukanova A, et al. | Biomed Res Int. 2022;2022:9426623. ##!http://doi.org/10.1155/2022/9426623
Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside##!2022 | Burska AN, Ilyassova B, et al. | Cells. 2022;11(21):3454. ##!http://doi.org/10.3390/cells11213454
Vitamin C enhances NF-κB-driven epigenomic reprogramming and boosts the immunogenic properties of dendritic cells##!2022 | Morante-Palacios O, Godoy-Tena G, et al. | Nucleic Acids Res. 2022;50(19):10981-10994. ##!http://doi.org/10.1093/nar/gkac941
No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial##!2022 | van Gorkom GNY, Boerenkamp LS, et al. | Nutrients. 2022;14(22):4784. ##!http://doi.org/10.3390/nu14224784
High-Dose Vitamin C in Advanced-Stage Cancer Patients##!2021 | Zasowska-Nowak A, Nowak PJ, et al. | Nutrients. 2021;13(3):735. ##!http://doi.org/10.3390/nu13030735
A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer##!2020 | Ou J, Zhu X, et al. | J Adv Res. 2020;24:175-182. ##!http://doi.org/10.1016/j.jare.2020.03.004
Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes##!2019 | Gillberg L, Ørskov AD, et al. | Clin Epigenetics. 2019;11:143. ##!http://doi.org/10.1186/s13148-019-0739-5
Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1##!2019 | Das AB, Kakadia PM, et al. | Blood Cancer J. 2019;9(10):82. ##!http://doi.org/10.1038/s41408-019-0242-4
Vitamin C and immune cell function in inflammation and cancer##!2018 | Ang A, Pullar JM, et al. | Biochem Soc Trans. 2018;46(5):1147-1159. ##!http://doi.org/10.1042/BST20180169
In vivo evidence of ascorbate involvement in the generation of epigenetic DNA modifications in leukocytes from patients with colorectal carcinoma, benign adenoma and inflammatory bowel disease##!2018 | Starczak M, Zarakowska E, et al. | J Transl Med. 2018;16:204. ##!http://doi.org/10.1186/s12967-018-1581-9
Symposium on Vitamin C##!2017 | Carr AC. | Antioxidants (Basel). 2017;6(4):94. ##!http://doi.org/10.3390/antiox6040094
Authors’ Perspective: What is the Optimum Intake of Vitamin C in Humans?##!2012 | Frei B, Birlouez-Aragon I, et al. | Critical Reviews in Food Science and Nutrition. 2012;52(9):815-829. ##!http://doi.org/10.1080/10408398.2011.649149
Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis##!2012 | Gonzalez MJ, Miranda Massari JR, et al. | J Orthomol Med. 2012;27(1):9-12. ##!https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031610/
Effect of the Supplemental Use of Antioxidants Vitamin C, Vitamin E, and Coenzyme Q10 for the Prevention and Treatment of Cancer##!2003 | Coulter I, Hardy M, et al. | Agency for Healthcare Research and Quality (US); 2003.
High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior Chemotherapy##!1985 | Moertel CG, Fleming TR, et al. | N Engl J Med. 1985;312(3):137-141. ##!http://doi.org/10.1056/NEJM198501173120301
Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.##!1976 | Cameron E, Pauling L. | Proc Natl Acad Sci U S A. 1976;73(10):3685-3689. ##!https://www.ncbi.nlm.nih.gov/pmc/articles/PMC431183/
The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer##!1974 | Cameron E, Campbell A. | Chemico-Biological Interactions. 1974;9(4):285-315. ##!http://doi.org/10.1016/0009-2797(74)90019-2
Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use | Annals of Internal Medicine##!Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use | Annals of Internal Medicine. | ##!https://www.acpjournals.org/doi/full/10.7326/0003-4819-140-7-200404060-00010?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org